NCT01750957View on ClinicalTrials.gov

A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Fragile X Syndrome
Interventions
DRUG

Placebo

orally daily, 12 weeks

DRUG

RO4917523

Dose A orally daily, 12 weeks

DRUG

RO4917523

Dose B orally daily, 12 weeks

Trial Locations (20)

10029

New York

19063

Media

20020

Washington D.C.

21205

Baltimore

29646

Greenwood

30033

Decatur

37212

Nashville

40202

Louisville

45229

Cincinnati

52242

Iowa City

60612

Chicago

77030

Houston

78258

San Antonio

80045

Aurora

90806

Long Beach

92108

San Diego

95817

Sacramento

98145

Seattle

01605

Worcester

68198-4160

Omaha

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01750957 - A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome | Biotech Hunter | Biotech Hunter